ABT-317

N/A

Report date: 2025/12/29 17:17:17

Base Information

Drug NameABT-317
Drug Alias NameABT-317ABT317
ClassificationOther
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSt Vincent's Institute Medical ResearchUniversity Of MelbourneAbbvie Bioresearch Center Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Bioresearch Center IncSt Vincent's Institute Medical ResearchUniversity Of Melbourne
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A